ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

GSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health Equity

  • Ten projects will receive funding to help address adult immunization gaps in communities across the country
  • GSK launched the COiMMUNITY Initiative in June to help increase adult immunization rates in the US through grant funding, increased data transparency and resource-sharing opportunities

GSK plc (LSE/NYSE: GSK) today announced the recipients of the inaugural grant program of the COiMMUNITY Initiative, a multipronged effort to support the design of a more systematic, collaborative and equitable approach to helping increase adult immunization rates in the US. Each grant-funded project is receiving between $50,000 and $175,000 out of a total $1 million in funding to help address long-standing barriers to adult immunization in the US.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231212489783/en/

Rob Truckenmiller, Senior Vice President, Head of US Vaccines, GSK, said: “Getting ahead of vaccine-preventable disease starts by investing in organizations who know their communities best, and I can’t think of a more deserving group of recipients for our first-ever COiMMUNITY Initiative grants. With these grants, our goal is to support innovative ways to encourage adult vaccination and help mitigate health inequities at both the local and national levels.”

The organizations that received funding submitted proposals that demonstrated innovative, ambitious and actionable ideas for boosting adult vaccination, such as building vaccine confidence among underserved patient populations through trusted community partners, creating engaging multilingual educational materials, and developing resources to support pharmacists and local health departments.

Hear from some of the 2023 COiMMUNITY Initiative grant recipients:

Liz Helms, President and CEO, California Chronic Care Coalition, said: “A successful vaccination program can alleviate the devastation of contagious diseases. We must meet people where they are – both online and in real life – if we hope to end inequities and social biases surrounding vaccine uptake. That’s what we aim to do with this funding, and we’re grateful for GSK’s support.”

Lisa Robertson, MPH, Executive Director, Indiana Immunization Coalition, said: “For our vulnerable immigrant and refugee communities, vaccination may not be top priority, and language and financial barriers present extra hurdles. With this grant, we hope to make vaccination more accessible to these communities by engaging with people in their own language and sharing information about clinics offering no-cost immunization.”

Other grant recipients include the American Lung Association, American Pharmacists Association (APhA), APhA Foundation, Asian Health Coalition, Global Health Living Foundation, Immunize Kansas Coalition, Pharmacy Quality Alliance, and The Arizona Partnership for Immunization.

Through the COiMMUNITY Initiative, GSK will continue to build on its commitment to help support long- lasting solutions to address adult immunization challenges through ongoing investments to empower stakeholders with actionable data, and models and best practices in adult vaccine confidence and delivery. These resources can be found on VaccineTrack.com.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors” in the company's Annual Report on Form 20-F for 2022, and Q2 Results for 2023.

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

Contacts

GSK enquiries

Kathleen Quinn

+1 202 603 5003 (Washington DC)

Alison Hunt

+1 540 742 3391 (Washington DC)

Investor Relations:

Jeff McLaughlin

+1 215 751 7002 (Philadelphia)

Frannie DeFranco

+1 215 751 4855 (Philadelphia)

Recent Quotes

View More
Symbol Price Change (%)
AMZN  217.14
+0.00 (0.00%)
AAPL  266.25
+0.00 (0.00%)
AMD  206.02
+0.00 (0.00%)
BAC  51.00
+0.00 (0.00%)
GOOG  289.98
+0.00 (0.00%)
META  589.15
+0.00 (0.00%)
MSFT  478.43
+0.00 (0.00%)
NVDA  180.64
+0.00 (0.00%)
ORCL  210.69
+0.00 (0.00%)
TSLA  395.23
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.